This site contains promotional information that is intended for UK healthcare professionals who have an interest in uveal melanoma. Adverse event reporting details can be found in the footer.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ . Adverse events should also be reported to Immunocore Ltd. by calling 00 800 74451111 (Freephone) or by email: medinfo.eu@immunocore.com.
Click here to view the Summary of Product Characteristics.
Click here to contact an IMMUNOCORE Representative
Job code: CM-GB-KIM-2400020 DOP: May 2025
KIMMTRAK▼ (tebentafusp) is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).2
KIMMTRAK (tebentafusp) is the only currently approved, NICE-recommended treatment specifically for mUM and demonstrated an improvement in OS benefit (3-year OS of 27% vs 18% with investigator’s choice [IC] of immune checkpoint inhibitors or chemotherapya), with a manageable adverse event (AE) profile and an AE-related discontinuation rate of 2% vs 5% with IC.2-5
aImmune checkpoint inhibitors – pembrolizumab or ipilimumab; chemotherapy – dacarbazine.
Explore KIMMTRAK’s key features, its pivotal efficacy and safety data, dosing and administration information, and resources for further information and support
About KIMMTRAK
Learn about the unmet need in mUM, and KIMMTRAK as first-line treatment in this setting and its mechanism of action
Efficacy
Find out about the KIMMTRAK pivotal Phase 3 trial design and explore the key efficacy data, including for up to 3 years of follow-up
Resources and support
Discover helpful resources for further support and information about KIMMTRAK.
AE, adverse event; HLA, human leukocyte antigen; IC, investigator’s choice of pembrolizumab, ipilimumab or dacarbazine; chemotherapy; mUM, metastatic uveal melanoma; OS, overall survival.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ . Adverse events should also be reported to Immunocore Ltd. by calling 00 800 74451111 (Freephone) or by email: medinfo.eu@immunocore.com.
Click here to view the Summary of Product Characteristics.
Click here to contact an IMMUNOCORE Representative
Job code: CM-GB-KIM-2400020 DOP: May 2025
